The challenge of managing coexistent type 2 diabetes and obesity

Research output: Contribution to journalArticle

Abstract

The presence of obesity with type 2 diabetes increases morbidity and mortality from each condition.
Excess adiposity accentuates insulin resistance and complicates the treatment of type 2 diabetes.
Glucagon-like peptide 1 receptor agonists promote weight loss, whereas metformin, dipeptidyl peptidase 4 inhibitors, and a glucosidase inhibitors are typically weight neutral.
The anabolic effects of increased insulin secretion and action restrict the benefits of treatment in obese patients.
New treatments should ideally reduce hyperglycaemia and excess adiposity.
Potential new treatments include analogues of intestinal and adipocyte hormones, inhibitors of renal glucose reabsorption and cellular glucocorticoid activation, and activators of cellular energy production.
Original languageEnglish
Article numberd1996
JournalBMJ
Volume342
Issue number7803
DOIs
Publication statusPublished - 23 Dec 2011

Fingerprint

Type 2 Diabetes Mellitus
Obesity
Adiposity
Dipeptidyl-Peptidase IV Inhibitors
Glucosidases
Gastrointestinal Hormones
Anabolic Agents
Metformin
Therapeutics
Adipocytes
Hyperglycemia
Glucocorticoids
Insulin Resistance
Weight Loss
Insulin
Morbidity
Weights and Measures
Glucose
Mortality

Bibliographical note

Creative Commons Attribution Non-Commerical License

Keywords

  • bariatric surgery
  • type 2 diabetes mellitus
  • humans
  • hypoglycemic agents
  • obesity
  • weight loss

Cite this

@article{b3133ebeb65f484480002b6c27b6d249,
title = "The challenge of managing coexistent type 2 diabetes and obesity",
abstract = "The presence of obesity with type 2 diabetes increases morbidity and mortality from each condition.Excess adiposity accentuates insulin resistance and complicates the treatment of type 2 diabetes.Glucagon-like peptide 1 receptor agonists promote weight loss, whereas metformin, dipeptidyl peptidase 4 inhibitors, and a glucosidase inhibitors are typically weight neutral.The anabolic effects of increased insulin secretion and action restrict the benefits of treatment in obese patients.New treatments should ideally reduce hyperglycaemia and excess adiposity.Potential new treatments include analogues of intestinal and adipocyte hormones, inhibitors of renal glucose reabsorption and cellular glucocorticoid activation, and activators of cellular energy production.",
keywords = "bariatric surgery, type 2 diabetes mellitus, humans, hypoglycemic agents, obesity, weight loss",
author = "Bailey, {Clifford J.}",
note = "Creative Commons Attribution Non-Commerical License",
year = "2011",
month = "12",
day = "23",
doi = "10.1136/bmj.d1996",
language = "English",
volume = "342",
journal = "BMJ",
issn = "0959-8138",
publisher = "BMJ Publishing Group",
number = "7803",

}

The challenge of managing coexistent type 2 diabetes and obesity. / Bailey, Clifford J.

In: BMJ, Vol. 342, No. 7803, d1996, 23.12.2011.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The challenge of managing coexistent type 2 diabetes and obesity

AU - Bailey, Clifford J.

N1 - Creative Commons Attribution Non-Commerical License

PY - 2011/12/23

Y1 - 2011/12/23

N2 - The presence of obesity with type 2 diabetes increases morbidity and mortality from each condition.Excess adiposity accentuates insulin resistance and complicates the treatment of type 2 diabetes.Glucagon-like peptide 1 receptor agonists promote weight loss, whereas metformin, dipeptidyl peptidase 4 inhibitors, and a glucosidase inhibitors are typically weight neutral.The anabolic effects of increased insulin secretion and action restrict the benefits of treatment in obese patients.New treatments should ideally reduce hyperglycaemia and excess adiposity.Potential new treatments include analogues of intestinal and adipocyte hormones, inhibitors of renal glucose reabsorption and cellular glucocorticoid activation, and activators of cellular energy production.

AB - The presence of obesity with type 2 diabetes increases morbidity and mortality from each condition.Excess adiposity accentuates insulin resistance and complicates the treatment of type 2 diabetes.Glucagon-like peptide 1 receptor agonists promote weight loss, whereas metformin, dipeptidyl peptidase 4 inhibitors, and a glucosidase inhibitors are typically weight neutral.The anabolic effects of increased insulin secretion and action restrict the benefits of treatment in obese patients.New treatments should ideally reduce hyperglycaemia and excess adiposity.Potential new treatments include analogues of intestinal and adipocyte hormones, inhibitors of renal glucose reabsorption and cellular glucocorticoid activation, and activators of cellular energy production.

KW - bariatric surgery

KW - type 2 diabetes mellitus

KW - humans

KW - hypoglycemic agents

KW - obesity

KW - weight loss

UR - http://www.scopus.com/inward/record.url?scp=79955441866&partnerID=8YFLogxK

U2 - 10.1136/bmj.d1996

DO - 10.1136/bmj.d1996

M3 - Article

C2 - 21490051

VL - 342

JO - BMJ

JF - BMJ

SN - 0959-8138

IS - 7803

M1 - d1996

ER -